Table 1 |
|||||||||
|
Summary of data arising from experiments utilizing 'omics' technologies. |
|||||||||
|
Study (Compartment) |
I (Plasma) |
II (Plasma) |
III (Plasma) |
IV (Plasma) |
V (Tissue) |
VIa (Tissue) |
VIb (Plasma) |
VIIa (Tissue) |
VIIb (Plasma) |
|
Disease area |
Organ Toxicity |
Cardio-vascular Disease |
Infectious Disease |
Neuro-muscular Disease |
Organ Toxicity |
Organ Toxicity |
Organ Toxicity |
||
|
Species |
Human |
Human |
Mouse |
Mouse |
Rat |
Rat |
Rat |
||
|
Platforms |
|||||||||
|
|
|||||||||
|
- GC/MS |
√ |
√ |
√ |
√ |
|||||
|
- Lipid LC/MS |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
|
- Polar LC/MS |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
|
- Proteomics (Mass Spectrometry) |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
||
|
- Proteomics (Multiplexed Immunoassay) |
√ |
√ |
|||||||
|
|
|||||||||
|
The metabolomic platforms utilized in various studies include GC/MS (gas chromatography coupled with mass spectrometry), Lipid LC/MS (liquid chromatography coupled with mass spectrometry platform targeting lipids) and Polar LC/MS (liquid chromatography coupled with mass spectrometry platform targeting polar metabolites). |
|||||||||
|
Guo et al. BMC Bioinformatics 2010 11:447 doi:10.1186/1471-2105-11-447 |
|||||||||
